Klaus Mauch

FiveT Capital AG (FiveT Capital) is an independent Swiss financial advisory firm which was founded by Johannes Minho Roth in 2006 which specializes in absolute return investment strategies. Formerly known as FiveT Capital Management AG, the firm aims to exploit opportunities in the European stock market, especially in Germany, by combining fundamental research and trading and execution. Based in Zurich, FiveT Capital manages the Cayman Islands-domiciled FiveMore Fund Ltd., backed primarily by high net-worth clients, funds of hedge funds and institutional investors. The firm operates their own trading and execution desk, allowing them to engage in proprietary trading and exploit market inefficiencies.

Fivet Capital AG (Private Banking) (Fivet Capital-PB) is the private banking division subsidiary of Fivet Capital AG, a hedge fund manager headquartered in Zurich, Switzerland. The firm was founded in 2006 and formerly known as FiveT Capital Wealth Management. Fivet Capital-PB provides wealth management and advisory services to high-net worth individuals, family offices and institutional investors.

FiveT Capital Holding AG provides investment related services. The private company is based in Pfäffikon, Switzerland. The Swiss company was founded by Johannes Minho Roth. Johannes Minho Roth has been the CEO since incorporation.

FiveT Fintech AG (FiveT Fintech) is a venture capital firm founded in 2018 by Francisco Fernandez Griñon and Alexander Christen. The firm is headquartered in Zurich, Switzerland.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

PreComb Therapeutics AG is a Swiss company that specializes in functional precision medicine for oncology and cancer. The company is based in Hombrechtikon, Switzerland. The company uses organoid and predictive technologies, as well as AI and data mining, to guide therapy and automate processes. The company also works in immune oncology and collaborate with other organizations such as 2curex, Xilis, USZ, DKFZ, and NCT. The company was founded in 2018 by Peter Steiner and Jens M. Kelm, with Jens M. Kelm serving as CEO since then.